Lamivudine Tablet, Film Coated
Product Images NDC 65862-025

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 65862-025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Virologic Response Through Week 48, Epv20001a,b (intent-to-treat) (Lamivudine Fig1)

The text describes a figure showing virologic response to treatment of subjects with HIV-1. The figure shows two treatment groups receiving different doses of Lamivudine. The x-axis represents treatment time in weeks while the y-axis shows the proportion of subjects with HIV-1 RNA less than 400 copies/mL. The figure indicates the percentage of responders, individuals who achieved and maintained HIV-1 RNA below 400 copies per mL at each visit, without discontinuation of treatment. The data was obtained using Roche AMPLICOR HIV-1 MONITOR assay.*

FDA Label Image

Package Label-principal Display Panel (150 mg (60 Tablets Bottle))

Each film-coated tablet contains 150 mg of lamivudine USP. The tablets are distributed by Aurobindo Pharma USA, Inc. and are made in India. The usual dosage and administration instructions can be found in the package insert. These tablets are prescription only and must be stored within the permitted temperature range. There is additional text related to printing zones and coding areas, but the meaning is unclear without more context.*

FDA Label Image

Package Label-principal Display Panel (150 mg Blister Carton 6 x 10 Unit-dose)

FDA Label Image

Package Label-principal Display Panel (300 mg (30 Tablets Bottle))

FDA Label Image

Package Label-principal Display Panel (300 mg Blister Carton 3 x 10 Unit-dose)

Lamivudine Tablets USP are a medication used to treat HIV, hepatitis B and hepatitis C infections. Each film-coated tablet contains 300 mg of amividing USP. The usual dosage and administration details can be found in the package insert. Store at a temperature between 20-25°C (68° to 77°F), with excursions permitted of 0-15° to 10-30°C (58" to B5F). The tablets come in a pack of 30 (3 X 10 Unit-dose). The manufacturer is Aurobindo Pharma USA Inc., and it is only available with a prescription.*

FDA Label Image

Chemical Structure (Lamivudine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.